CAR

Antigen

Institute

Sample

Participants Effective Number

Outcome

Year of Publishing

Ref.

Number (M/F)

Age

CD19 2^nd CD28

National Cancer Institute

15^g (8/7)

51.67 ± 11.22

15^g

Rate of CR: 53%;

Rate of PR: 26%;

2014

[112]

CD19 (the generation is unknown)

Fred Hutchinson cancer Research

28 h, f

Adult

24 ⁱ

8.3% and PR rate is 41.7%; Addition of fludarabine received in 16 patients. lymphodepletion, the rate of CR is 42% and PR rate is 25%.

2015

[138]

CD30 2^nd 4-1BB

Chinese PLA

general Hospital

18 (13/5)

31

18

PR rate: 39%; SD rate: 33%

2016

[139]